Journal of Clinical Psychiatry

Subject Index to Volume 53: January 1992 Through December 1992

Academic Highlights
New directions in antidepressant therapy: a review of sertraline, a unique serotonin reuptake inhibitor. Sept 333–340
Novel selective serotonin reuptake inhibitors, part I. Mar 107–112
Novel selective serotonin reuptake inhibitors, part II. June 216–221

Acquired Immunodeficiency Syndrome
AIDS-related psychosis with catatonia responding to low-dose lorazepam [letter]. Scamvougeras, Nov 414–415
Catatonia in a patient with AIDS-related dementia [letter]. Snyder, Nov 414
Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial. White, May 153–156

Adolescents
Childhood obsessive compulsive disorder. Rapoport, Apr suppl 11–16
Misdiagnosed bipolar disorder in adolescents in a special educational school and treatment program. Isaac, Apr 133–136

Affective Disorders see also Bipolar Disorder; Depression; Mania; Seasonal Affective Disorder
Introduction and overview to clinical applications of neuroSPECT in psychiatry. Schuckit, Nov suppl 3–6

Agitation
New possible indications of pimozide [letter]. Iruela; Opler reply, May 172–173

Agranulocytosis
Clozapine-induced agranulocytosis in a native American: HLA typing and further support for an immune-mediated mechanism. Pfister, July 242–244
Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report. Barnas, July 245–247

Akathisia
Akathisia, suicidality, and fluoxetine. Hamilton, Nov 401–406
Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? Levin, July 248–251

Allergic Reaction
Injection site reactions [letter]. Hay, July 256

Alpidem
Clarification of alpidem as an antidepressant [letter]. George; Tollefson reply, Feb 68–69

Alzheimer's Disease see also Dementia
Nonsedating treatments for Alzheimer's patients with behavioral problems [letter]. Hawkins; Goad reply, Mar 101–102

Amantadine
Treatment of fluoxetine-induced anorgasmia with amantadine [letter]. Balogh, June 212–213

Amphetamine
Is tranylcypromine really metabolized to amphetamine [letter]? Jefferson; Zajecka reply, Dec 450–451

Anorexia Nervosa see also Bulimia; Eating Disorders
Preliminary investigation of the lifetime prevalence of anorexia and bulimia nervosa in patients with obsessive compulsive disorder. Rubenstein, Sept 309–314

Anticholinergic Agents
"Gedankenlautwerden" and datura intoxication [letter]. Goates, Apr 137

Antidepressants see also specific drugs
Acute tryptophan depletion: a method of studying antidepressant action. Miller, Oct suppl 28–35
Imperfect drugs in an imperfect world [editorial]. Gelenberg, Feb 39–40
Introduction. Issues in the treatment of major depression: selection, efficacy, and safety. Blazer, Sept suppl 3–4
Medical consequences of the selection of an antidepressant. Nierenberg, Sept suppl 19–24
Nifedipine and nonresponse to antidepressants [letter]. Fadden; Nierenberg reply, Nov 416–417
Somatic therapy for major depressive disorder: selection of an antidepressant. Preskorn, Sept suppl 5–18
T_3 augmentation of antidepressant treatment in T_4-replaced thyroid patients. Cooke, Jan 16–18
Treating the depressed patient with cardiovascular problems. Roose, Sept suppl 25–31
Tricyclic antidepressant-induced seizures and plasma drug concentration. Preskorn, May 160–162
Tricyclic antidepressant triggers mania in patient with organic affective disorder [letter]. Santos, Oct 377–378

Anxiety
Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD [letter]. Novac, Feb 67
Regional cerebral blood flow imaging with SPECT in psychiatric disease: focus on schizophrenia, anxiety disorders, and substance abuse. Woods, Nov suppl 20–25

Autism
Double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Fankhauser, Mar 77–82

Baclofen
Case of baclofen-induced psychotic depression [letter]. Sommer, June 211–212

Behavioral Disorders
Nonsedating treatments for Alzheimer's patients with behavioral problems [letter]. Hawkins; Goad reply, Mar 101–102

Benzodiazepines
Clinical distinctions between long-acting and short-acting benzodiazepines. Mendelson, Dec suppl 4–7
Clinical uses and advantages of low doses of benzodiazepine hypnotics. Vogel, June suppl 19–22
Closing remarks. Use of benzodiazepine hypnotics: a scientific examination of a clinical controversy. Gelenberg, Dec suppl 87
Closing remarks. Use of benzodiazepine hypnotics: a scientific examination of a clinical controversy. Kupfer, Dec suppl 84–85
Closing remarks. Use of benzodiazepine hypnotics: a scientific examination of a clinical controversy. Wincor, Dec suppl 85–87
Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. Jonas, Dec suppl 19–31
Introduction. Use of benzodiazepine hypnotics: a scientific examination of a clinical controversy. Gelenberg, Dec suppl 3
Issues in the use of benzodiazepine therapy. Roth, June suppl 14–18
Pharmacology of benzodiazepine hypnotics. Greenblatt, June suppl 7–13

Bipolar Disorder
Bipolar disorder and Crohn's disease [letter]. Dommisse, Jan 29
Bupropion in the treatment of bipolar disorders: the same old story? Fogelson, Dec 443–46
Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD [letter]. Novac, Feb 67
Misdiagnosed bipolar disorder in adolescents in a special educational school and treatment program. Isaac, Apr 133–136

Blood Levels
Do monoamine oxidase inhibitors alter carbamazepine blood levels [letter]? Jefferson, July 258
Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. Keck Jr, Apr 127–129
Tricyclic antidepressant-induced seizures and plasma drug concentration. Preskorn, May 160–162

Books Reviewed
Addonizio G, Susman VL: *Neuroleptic Malignant Syndrome: A Clinical Approach*. Gold Jr, Jan 31
Amchin J: *Psychiatric Diagnosis: A Biopsychosocial Approach*. Djenderedjian and Ritchie, July 259–260
Arndt AB Jr: *Gender Disorders and the Paraphilias*. Segraves, June 215
Becker J, Kleinman A (eds): *Psychosocial Aspects of Depression*. Keitner, Feb 71
Becker RE, Giacobini E (eds): *Alzheimer's Disease: Current Research in Early Diagnosis*. Cummings, Mar 105
Butcher JN, Graham JR, Williams CL, Ben-Porath YS: *Development and Use of the MMPI-2 Content Scales*. Kores, Mar 105–106
Committee on Psychiatry and Law of the Group for the Advancement of Psychiatry: *The Mental Health Professional and the Legal System*. Tanay, Feb 70

Cutting J: *The Right Cerebral Hemisphere and Psychiatric Disorders*. Nasrallah, Apr 140
Dulcan MK, Popper CW: *Concise Guide to Child and Adolescent Psychiatry*. Hill, Feb 70–71
Esman AH: *Adolescence and Culture*. King, Aug 298
Evangelista A: *Dictionary of Hypnotism*. Battle, Mar 106
Exner JE Jr: *The Rorschach: A Comprehensive System, Vol. 2: Interpretation, 2nd Ed.* Battle, Sept 331–332
Falco KL: *Psychotherapy With Lesbian Clients: Theory Into Practice*. Surawicz, Sept 332
Feinstein SC (ed): *Adolescent Psychiatry, Volume 17*. Pomeroy, Feb 71
Greenspan SL, Greenspan NT: *The Clinical Interview of the Child*. Utley, June 214–215
Harper-Giuffre H, MacKenzie KR (eds): *Group Psychotherapy for Eating Disorders*. Larocca, Nov 418
Hendren RL, Berlin IN (eds): *Psychiatric Inpatient Care of Children and Adolescents: A Multi-Cultural Approach*. Soltys, Apr 140–141
Horowitz MJ (ed): *Person Schemas and Maladaptive Interpersonal Patterns*. St. John, Sept 331
Howells JG (ed): *The Concept of Schizophrenia: Historical Perspectives*. Gold Jr, May 175–176
Koulack D: *To Catch a Dream*. Mendelson, Aug 297
Levine SB: *Sex Is Not Simple*. Surawicz, Jan 32
Lewis JM: *Swimming Upstream: Teaching and Learning Psychotherapy in a Biological Era*. Usdin, Jan 32
Locurto C: *Sense and Nonsense About IQ: The Case for Uniqueness*. Brink, May 176
Myers WA (ed): *New Techniques in the Psychotherapy of Older Patients*. Blashko, July 259
Rhodes LA: *Emptying Beds: The Work of an Emergency Psychiatric Unit*. Stovall, June 215
Roy-Byrne PP, Cowley DS (eds): *Benzodiazepines in Clinical Practice: Risks and Benefits*. Billings, Jan 31–32
Schlaifer C, Freeman L: *Heart's Work: Civil War Heroine and Champion of the Mentally Ill, Dorothea Lynde Dix*. Surawicz, Nov 418
Schwartz HJ, Silver A-L (eds): *Illness in the Analyst*. Mazza, Oct 382
Scrignar CB: *From Panic to Peace of Mind: Overcoming Panic and Agoraphobia*. Billings, Aug 297–298
Serafica FC, Schwebel AI, Russell RK, Isaac PD, Myers LB (eds): *Mental Health of Ethnic Minorities. Surawicz, June 214*
Smith GR Jr: *Somatization Disorder in the Medical Setting*. Beitman, May 175
Socarides CW, Volkan VD (eds): *The Homosexualities: Reality, Fantasy, and the Arts*. Levine, Oct 381
Socarides CW, Volkan VD (eds): *The Homosexualities and the Therapeutic Process*. Stone, Oct 381–382
Stone MH: Unreviewed books [letter]. June 214
Stotland NL (ed): *Psychiatric Aspects of Abortion*. Surawicz, May 175
Stuber ML (ed): *Children and AIDS*. Thaggard, Nov 419
The Workgroup on Psychiatric Practice in the Juvenile Court: *Handbook of Psychiatric Practice in the Juvenile Court*. Bernet, Sept 331
Trad PV: *Interventions With Infants and Parents: The Theory and Practice of Previewing*. Soltys, Nov 418–419
Turner SM, Calhoun KS, Adams HE (eds): *Handbook of Clinical Behavior Therapy*. Mavissakalian, Nov 419
Volkow ND, Wolf AP (eds): *Positron Emission Tomography in Schizophrenia Research*. Gold Jr, Apr 140
Weeks GR (ed): *Promoting Change Through Paradoxical Therapy, rev. ed.* Rodgers, July 260
Weiner MF (ed): *The Dementias: Diagnosis and Management*. Stoudemire, July 260
Winokur G: *Mania and Depression: A Classification of Syndrome and Disease*. Amado, Dec 452
Yates A: *Compulsive Exercise and the Eating Disorders: Toward an Integrated Theory of Activity*. Casper, Apr 141

Brain Disorders
Fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder [letter]. George; Hoehn-Saric reply, Oct 379–380

Brain Injuries
Head injury and mood disturbance [letter]. Miller, May 171–172
Methylphenidate and seizure frequency in brain injured patients with seizure disorders. Wroblewski, Mar 86–89

Bulimia see also Anorexia Nervosa; Eating Disorders
Lack of association between fluoxetine and suicidality in bulimia nervosa. Wheadon, July 235–241
Personality disorder diagnoses in patients with bulimia nervosa: clinical correlates and changes with treatment. Ames-Frankel, Mar 90–96
Preliminary investigation of the lifetime prevalence of anorexia and bulimia nervosa in patients with obsessive compulsive disorder. Rubenstein, Sept 309–314
Symptom relapse in bulimia nervosa and obsessive compulsive disorder after treatment with serotonin antagonists [letter]. Hollander, Jan 28

Bupropion
Bupropion in the treatment of bipolar disorders: the same old story? Fogelson, Dec 443–446
Catatonia associated with bupropion treatment [letter]. Jackson, June 210
Efficacy of bupropion in the winter depression: results of an open trial. Dilsaver, July 252–255
Falling backward in two elderly patients taking bupropion. Szuba, May 157–159
Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD [letter]. Novac, Feb 67
Organic mental disorders associated with bupropion in three patients. Ames, Feb 53–55

Capgras Syndrome
Case of Capgras-Fregoli syndrome [letter]. Silva, Feb 67–68

Carbamazepine
Carbamazepine-associated thrombocytopenia [letter]. Gordon; Tohen reply, Oct 378–379
Do monoamine oxidase inhibitors alter carbamazepine blood levels [letter]? Jefferson, July 258

Cardiovascular Diseases
Treating the depressed patient with cardiovascular problems. Roose, Sept suppl 25–31

Catatonia
AIDS-related psychosis with catatonia responding to low-dose lorazepam [letter]. Scamvougeras, Nov 414–415
Catatonia associated with bupropion treatment [letter]. Jackson, June 210
Catatonia in a patient with AIDS-related dementia [letter]. Snyder, Nov 414
NMS and lethal catatonia [letter]. Weller; DasGupta reply, Aug 294–295

Cerebral Blood Flow
Regional cerebral blood flow imaging with SPECT in psychiatric disease: focus on schizophrenia, anxiety disorders, and substance abuse. Woods, Nov suppl 20–25

Cerebral Stroke
Depression and cerebral stroke. Catapano, 1990 Sept suppl 9–12; Notice to the readers, Aug 293
Efficacy and side effects of methylphenidate for poststroke depression. Lazarus, Dec 447–449

Cerebrovascular Disorders
Comparison of SPECT applications in neurology and psychiatry. Devous, Nov suppl 13–19

Children
Childhood obsessive compulsive disorder. Rapoport, Apr suppl 11–16

Chronic Fatigue Syndrome
Pathogenesis of chronic fatigue syndrome [letter]. Fuchs; Krupp reply, Aug 296

Classification
DSM-III-R brief reactive psychosis among Air Force recruits. Beighley, Aug 283–288

Clonidine
Double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Fankhauser, Mar 77–82

Clozapine
Clozapine-induced agranulocytosis in a native American: HLA typing and further support for an immune-mediated mechanism. Pfister, July 242–244
Clozapine-induced myoclonic jerks and drop attacks [letter]. Berman, Sept 329–330
Emergence of obsessive compulsive symptoms during treatment with clozapine. Baker, Dec 439–442
Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. Wolk, Oct 373–376
Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report. Barnas, July 245–247
NMS and lethal catatonia [letter]. Weller; DasGupta reply, Aug 294–295
Restraint, seclusion and clozapine. Mallya, Nov 395–397
Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? Levin, July 248–251

Cognition Disorders
Introduction and overview to clinical applications of neuroSPECT in psychiatry. Schuckit, Nov suppl 3–6

Cognitive Therapy
Pilot sequential study of cognitive therapy and

pharmacotherapy of atypical depression. Mercier, May 166–170
Comorbidity
Paraphilias, nonparaphilic sexual addictions, and social phobia [letter]. Golwyn, Sept 330
Personality disorder diagnoses in patients with bulimia nervosa: clinical correlates and changes with treatment. Ames-Frankel, Mar 90–96
Preliminary investigation of the lifetime prevalence of anorexia and bulimia nervosa in patients with obsessive compulsive disorder. Rubenstein, Sept 309–314
Prevalence of personality disorders in 210 women with eating disorders. Herzog, May 147–152
Psychiatric comorbidity and suicidality among intravenous drug users. Dinwiddie, Oct 364–369
Simultaneous major depression and panic disorder: treatment with electroconvulsive therapy. Figiel, Jan 12–15
Treating the depressed patient with cardiovascular problems. Roose, Sept suppl 25–31
Continuation Treatment
Long-term clinical management of depressive disorders. Burrows, Mar suppl 32–35
Corrections
Depression and cerebral stroke. Catapano, 1990 Sept suppl 9–12; Notice to the readers, Aug 293
Crohn's Disease
Bipolar disorder and Crohn's disease [letter]. Dommisse, Jan 29
Cyproheptadine
Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment [letter]. Cohen, May 174
Datura
"Gedankenlautwerden" and datura intoxication [letter]. Goates, Apr 137
de Clerambault's Syndrome
de Clerambault's syndrome [letter]. Vicente; Giannini reply, Apr 138–139
Delirium
Ofloxacin-induced delirium [letter]. Fennig, Apr 137–138
Should psychostimulants be used to treat delirious patients with depressed mood [letter]? Levenson; Ahmed reply, Feb 69
Dementia see also Alzheimer's Disease
Catatonia in a patient with AIDS-related dementia [letter]. Snyder, Nov 414
Comparison of SPECT applications in neurology and psychiatry. Devous, Nov suppl 13–19
Depression
Bupropion in the treatment of bipolar disorders: the same old story? Fogelson, Dec 443–446
Case of baclofen-induced psychotic depression [letter]. Sommer, June 211–212
Clinical course of panic disorder and depression. Keller, Mar suppl 5–8
Closing remarks. Current perspectives on panic disorder and major depression. Hirschfeld, Mar suppl 36
Comparison of SPECT applications in neurology and psychiatry. Devous Sr, Nov suppl 13–19
Depression and cerebral stroke. Catapano, 1990 Sept suppl 9–12; Notice to the readers, Aug 293
Dexamethasone for the treatment of depression [letter]. Coplan, Aug 293
Double-blind comparison of paroxetine, imipramine, and placebo in major depression. Shrivastava, Feb suppl 48–51
Double-blind, placebo-controlled study of paroxetine in depressed outpatients. Kiev, Feb suppl 27–29
Efficacy and safety of paroxetine compared with placebo in outpatients with major depression. Rickels, Feb suppl 30–32
Efficacy and side effects of methylphenidate for poststroke depression. Lazarus, Dec 00–00
Introduction. Current perspectives on panic disorder and major depression. Hirschfeld, Mar suppl 3–4
Introduction. Issues in the treatment of major depression: selection, efficacy, and safety. Blazer, Sept suppl 3–4
Long-term clinical management of depressive disorders. Burrows, Mar suppl 32–35
Long-term treatments of recurrent depressive disorders. Thase, Sept suppl 32–44
Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial. White, May 153–156
Neurochemical alterations of serotonergic neuronal systems in depression. Risch, Oct suppl 3–7
Novel selective serotonin reuptake inhibitors, part I. Mar Academic Highlights 107–112
Paroxetine in major depression a double-blind trial with imipramine and placebo. Cohn, Feb suppl 52–56
Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Feighner, Feb suppl 44–47
Paroxetine versus placebo: a double-blind comparison in depressed patients. Claghorn, Dec 434–438
Pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression. Mercier, May 166–170
Placebo-controlled trial of paroxetine in the treatment of major depression. Smith, Feb suppl 36–39
Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? Cain, Aug 272–277
Premenstrual exacerbation of depression: one process or two? Yonkers, Aug 289–292
Recent developments in the acute somatic treatment of major depression. Schatzberg, Mar suppl 20–25
Safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Claghorn, Feb suppl 33–35
Serotonin activity in psychotic (delusional) major depression. Schatzberg, Oct suppl 52–55
Should psychostimulants be used to treat delirious patients with depressed mood [letter]? Levenson; Ahmed reply, Feb 69
Simultaneous major depression and panic disorder: treatment with electroconvulsive therapy. Figiel, Jan 12–15
Six-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Fabre, Feb suppl 40–43
Somatic therapy for major depressive disorder: selection of an antidepressant. Preskorn, Sept suppl 5–18
Suicide risk factors in depressive disorders and in panic disorder. Fawcett, Mar suppl 9–13
Treating the depressed patient with cardiovascular problems. Roose, Sept suppl 25–31
Treatment of depression in special populations. Reynolds, Sept suppl 45–53
Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. Thase, Jan 5–11
Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Dunner, Feb suppl 57–60
Use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. Malone Jr, Apr 130–132
Dexamethasone
Dexamethasone for the treatment of depression [letter]. Coplan, Aug 293
Diagnosis
Comparison of diagnostic criteria for neuroleptic malignant syndrome. Gurrera, Feb 56–62
Diagnosis and treatment of insomnia and risks associated with lack of treatment. Nino-Murcia, Dec suppl 43–47
Diagnostic confusion in treatment-refractory psychotic patients. Smith, June 197–200
DSM-III-R brief reactive psychosis among Air Force recruits. Beighley, Aug 283–288
Epidemiology and differential diagnosis of obsessive compulsive disorder. Rasmussen, Apr suppl 4–10
Examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder. Gelernter, Jan 23–27
Factitious disorders with psychological symptoms. Popli, Sept 315–318
"Gedankenlautwerden" and datura intoxication [letter]. Goates, Apr 137
Misdiagnosed bipolar disorder in adolescents in a special educational school and treatment program. Isaac, Apr 133–136
Usefulness of screening EEGs in psychiatric inpatients [letter]. Schwitzer; Warner reply, Sept 327–328
Dosage
Optimal dose regimen for paroxetine. Dunner, Feb suppl 21–26
Doxepin
Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Dunner, Feb suppl 57–60
Drug Administration Routes
Depot neuroleptic therapy: an underutilized treatment option. Glazer, Dec 426–433
Double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Fankhauser, Mar 77–82
Use of low-dose intranasal midazolam to treat panic disorder: a pilot study. Schweizer, Jan 19–22
Drug Dependence/Withdrawal
Loperamide dependence [letter]. Hill, Dec 450
Drug Discontinuation
Loperamide dependence [letter]. Hill, Dec 450
Medication discontinuation in panic disorder. Ballenger, Mar suppl 26–31
Drug Side Effects
Case of baclofen-induced psychotic depression [letter]. Sommer, June 211–212
Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature. Rothschild, Dec suppl 69–79
Falling backward in two elderly patients taking

bupropion. Szuba, May 157–159
Medical consequences of the selection of an antidepressant. Nierenberg, Sept suppl 19–24
Parnate formulation change [letter]. Malen; Murabito reply, Sept 328–329
Drug Therapy
Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. Lenox, Feb 47–52
Fluoxetine-lithium treatment for kleptomania [letter]. Burstein, Jan 28–29
Imperfect drugs in an imperfect world [editorial]. Gelenberg, Feb 39–40
Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial. White, May 153–156
Pharmacotherapy of obsessive compulsive disorder. Goodman, Apr suppl 29–37
Pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression. Mercier, May 166–170
Possible trazodone potentiation of fluoxetine: a case series. Nierenberg, Mar 83–85
Potassium supplementation in lithium patients: a timely intervention or premature speculation? Jefferson, Oct 370–372
Psychopharmacological screening criteria: APA committee on research on psychiatric treatments [special article]. Kane, June 184–196
Treatments for panic disorder. Klerman, Mar suppl 14–19
Trends in the pharmacologic treatment of insomnia. Walsh, Dec suppl 10–17
Usefulness of screening EEGs in psychiatric inpatients [letter]. Schwitzer; Warner reply, Sept 327–328
Dystonia
Acute dystonia and fluoxetine [letter]. Black, Sept 327
Eating Disorders see also Anorexia Nervosa; Bulimia
Dangerous driving and eating disorders [letter]. Gupta, Nov 416
Fluoxetine treatment of slow eating [letter]. Galynker, Aug 295–296
Prevalence of personality disorders in 210 women with eating disorders. Herzog, May 147–152
Editorials
If not now, when [editorial]? Gelenberg, Aug 266
Imperfect drugs in an imperfect world [editorial]. Gelenberg, Feb 39–40
In memoriam: William W.K. Zung, 1929–1992 [editorial]. Brodie, June 182–183
To all a good year [editorial]. Gelenberg Dec 424–425
EEG see Electroencephalography
Electroconvulsive Therapy
Simultaneous major depression and panic disorder: treatment with electroconvulsive therapy. Figiel, Jan 12–15
Symptomatic predictors of ECT response in medication-nonresponsive manic patients. Schnur, Feb 63–66
Electroencephalography
Usefulness of screening EEGs in psychiatric inpatients [letter]. Schwitzer; Warner reply, Sept 327–328
Enalapril
Effect of enalapril on serum lithium levels in healthy men. DasGupta, Nov 398–400
Epidemiology
Epidemiology and differential diagnosis of obsessive compulsive disorder. Rasmussen, Apr suppl 4–10
New epidemiologic findings about insomnia and its treatment. Balter, Dec suppl 34–39
Epilepsy
Comparison of SPECT applications in neurology and psychiatry. Devous Sr, Nov suppl 13–19
Paranoid psychosis, epidermoid tumor, and epilepsy: "symptomatic" psychosis or coincidence [letter]? Weller, July 257–258
Factitious Disorders
Factitious disorders with psychological symptoms. Popli, Sept 315–318
Fluoxetine
Acute dystonia and fluoxetine [letter]. Black, Sept 327
Akathisia, suicidality, and fluoxetine. Hamilton, Nov 401–406
Clinical characteristics of trichotillomania and its response to fluoxetine. Winchel, Sept 304–308
Does fluoxetine exacerbate Parkinson's disease? Caley, Aug 278–282
Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD [letter]. Novac, Feb 67
Fluoxetine and suicidality [letter]. Pearlman; Rothschild reply, July 256
Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. Kafka, Oct 351–358
Fluoxetine treatment of slow eating [letter]. Galynker, Aug 295–296
Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. Jacobsen, Apr 119–122
Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment [letter]. Cohen, May 174
Fluoxetine-lithium treatment for kleptomania [letter]. Burstein, Jan 28–29
Lack of association between fluoxetine and suicidality in bulimia nervosa. Wheadon, July 235–241
Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? Cain, Aug 272–277
Possible trazodone potentiation of fluoxetine: a case series. Nierenberg, Mar 83–85
Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. Keck Jr, Apr 127–129
Single-dose fluoxetine in management of premenstrual syndrome [letter]. Daamen, June 210–211
Suicidal and homicidal ideations emerging during a placebo period [letter]. Dominguez, May 171
Suicidality and fluoxetine revisited [letter]. Masand; Fava reply, Mar 102–103
Treatment of fluoxetine-induced anorgasmia with amantadine [letter]. Balogh, June 212–213
Use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. Malone Jr, Apr 130–132
Fluvoxamine
Fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder [letter]. George; Hoehn-Saric reply, Oct 379–380
Fregoli Syndrome
Case of Capgras-Fregoli syndrome [letter]. Silva, Feb 67–68
Fregoli syndrome: an unusual appearance in fiction [letter]. Schneck, Mar 101
Geriatric Psychiatry
Insomnia in the elderly. Monane, June suppl 23–28
Treatment of depression in special populations. Reynolds III, Sept suppl 45–53
Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Dunner, Feb suppl 57–60
Gilles de la Tourette's Syndrome
Fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder [letter]. George; Hoehn-Saric reply, Oct 379–380
Sensory phenomena associated with Gilles de la Tourette's syndrome. Cohen, Sept 319–323
Grief
Treatment of depression in special populations. Reynolds III, Sept suppl 45–53
Haloperidol
Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. Lenox, Feb 47–52
High incidence of haloperidol decanoate injection site reactions [letter]. Reinke; Hamann reply, Nov 415–416
Health Care
If not now, when [editorial]? Gelenberg, Aug 266
Homicide
Suicidal and homicidal ideations emerging during a placebo period [letter]. Dominguez, May 171
Hormones
Oral contraceptives and panic disorder. Deci, May 163–165
Human Immunodeficiency Virus
HIV-related psychosis [letter]. El-Mallakh, Aug 293–294
Hypertension
Is tranylcypromine really metabolized to amphetamine [letter]? Jefferson; Zajecka reply, Dec 450-451
Imipramine
Double-blind comparison of paroxetine, imipramine, and placebo in major depression. Shrivastava, Feb suppl 48–51
Paroxetine in major depression: a double-blind trial with imipramine and placebo. Cohn, Feb suppl 52–56
Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Feighner, Feb suppl 44–47
Six-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Fabre, Feb suppl 40–43
Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. Thase, Jan 5–11
Injections
High incidence of haloperidol decanoate injection site reactions [letter]. Reinke; Hamann reply, Nov 415–416
Injection site reactions [letter]. Hay, July 256
Insomnia
Diagnosis and treatment of insomnia and risks associated with lack of treatment. Nino-

Murcia, Dec suppl 43–47
New epidemiologic findings about insomnia and its treatment. Balter, Dec suppl 34–39
Pharmacist's role in the recognition and management of insomnia. Wincor, Dec suppl 80–83
Trends in the pharmacologic treatment of insomnia. Walsh, Dec suppl 10–17
Intermetamorphosis Syndrome
Intermetamorphosis syndrome [letter]. De Leon, Jan 29–30
Journal of Clinical Psychiatry
If not now, when [editorial]? Gelenberg, Aug 266
To all a good year [editorial]. Gelenberg Dec 424–425
Kleptomania
Fluoxetine-lithium treatment for kleptomania [letter]. Burstein, Jan 28–29
L-Triiodothyronine
T_3 augmentation of antidepressant treatment in T_4-replaced thyroid patients. Cooke, Jan 16–18
Lithium
Effect of enalapril on serum lithium levels in healthy men. DasGupta, Nov 398–400
Fluoxetine-lithium treatment for kleptomania [letter]. Burstein, Jan 28–29
Potassium supplementation in lithium patients: a timely intervention or premature speculation? Jefferson, Oct 370–372
Loperamide
Loperamide dependence [letter]. Hill, Dec 450
Lorazepam
Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. Lenox, Feb 47–52
AIDS-related psychosis with catatonia responding to low-dose lorazepam [letter]. Scamvougeras, Nov 414–415
Catatonia in a patient with AIDS-related dementia [letter]. Snyder, Nov 414
NMS and lethal catatonia [letter]. Weller; DasGupta reply, Aug 294–295
Lupus Anticoagulant
Phenothiazine-induced lupus anticoagulant [letter]. Kaslow, Mar 103–104
Maintenance Treatment see also Continuation Treatment
Long-term treatments of recurrent depressive disorders. Thase, Sept suppl 32–44
Mania
Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. Lenox, Feb 47–52
Bupropion in the treatment of bipolar disorders: the same old story? Fogelson, Dec 443–446
HIV-related psychosis [letter]. El-Mallakh, Aug 293–294
Mania self-induced with cough syrup [letter]. Mendez, May 173–174
Symptomatic predictors of ECT response in medication-nonresponsive manic patients. Schnur, Feb 63–66
Tricyclic antidepressant triggers mania in patient with organic affective disorder [letter]. Santos, Oct 377–378
Medical Illness
Psychiatrists and physical illness: clarification [letter]. DuRand, June 213
Sleep disorders in the medically ill patient. Moran, June suppl 29–36
Menstrual Cycle
Premenstrual exacerbation of depression: one process or two? Yonkers, Aug 289–292
Methylphenidate
Efficacy and side effects of methylphenidate for poststroke depression. Lazarus, Dec 447–449
Methylphenidate and seizure frequency in brain injured patients with seizure disorders. Wroblewski, Mar 86–89
Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial. White, May 153–156
Midazolam
Use of low-dose intranasal midazolam to treat panic disorder: a pilot study. Schweizer, Jan 19–22
Monoamine Oxidase Inhibitors
Do monoamine oxidase inhibitors alter carbamazepine blood levels [letter]? Jefferson, July 258
Is tranylcypromine really metabolized to amphetamine [letter]? Jefferson; Zajecka reply, Dec 450–451
Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. Thase, Jan 5–11
Mood
Head injury and mood disturbance [letter]. Miller, May 171–172
Munchausen Syndrome
Factitious disorders with psychological symptoms. Popli, Sept 315–318
Myoclonus
Clozapine-induced myoclonic jerks and drop attacks [letter]. Berman, Sept 329–330
Nadolol
Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. Ratey, Feb 41–46
Neuroleptic Malignant Syndrome
Comparison of diagnostic criteria for neuroleptic malignant syndrome. Gurrera, Feb 56–62
NMS and lethal catatonia [letter]. Weller; DasGupta reply, Aug 294–295
Neuroleptics see also specific drugs
Depot neuroleptic therapy: an underutilized treatment option. Glazer, Dec 426–433
Response of negative symptoms of schizophrenia to neuroleptic treatment. Serban, July 229–234
Nifedipine
Nifedipine and nonresponse to antidepressants [letter]. Fadden; Nierenberg reply, Nov 416–417
Obsessive Compulsive Disorder
Childhood obsessive compulsive disorder. Rapoport, Apr suppl 11–16
Clinical characteristics of trichotillomania and its response to fluoxetine. Winchel, Sept 304–308
Comparison of SPECT applications in neurology and psychiatry. Devous Sr, Nov suppl 13–19
Emergence of obsessive compulsive symptoms during treatment with clozapine. Baker, Dec 439–442
Epidemiology and differential diagnosis of obsessive compulsive disorder. Rasmussen, Apr suppl 4–10
Fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder [letter]. George; Hoehn-Saric reply, Oct 379–380
Fluoxetine treatment of slow eating [letter]. Galynker, Aug 295–296
Integrated approach to treatment of obsessive compulsive disorder. Greist, Apr suppl 38–41
Introduction. Obsessive compulsive disorder: integrating theory and practice. Goodman, Apr suppl 3
Pharmacotherapy of obsessive compulsive disorder. Goodman, Apr suppl 29–37
Preliminary investigation of the lifetime prevalence of anorexia and bulimia nervosa in patients with obsessive compulsive disorder. Rubenstein, Sept 309–314
Serotonergic antidepressants and their efficacy in obsessive compulsive disorder. Dominguez, Oct suppl 56–59
Serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. Barr, Apr suppl 17–28
Symptom relapse in bulimia nervosa and obsessive compulsive disorder after treatment with serotonin antagonists [letter]. Hollander, Jan 28
Treatment outcome of obsessive compulsive disorder with comorbid social phobia. Carrasco, Nov 387–391
Ofloxacin
Ofloxacin-induced delirium [letter]. Fennig, Apr 137–138
Organic Mental Disorders
Organic mental disorders associated with bupropion in three patients. Ames, Feb 53–55
Treatment of depression in special populations. Reynolds III, Sept suppl 45–53
Tricyclic antidepressant triggers mania in patient with organic affective disorder [letter]. Santos, Oct 377–378
Panic
Clinical course of panic disorder and depression. Keller, Mar suppl 5–8
Closing remarks. Current perspectives on panic disorder and major depression. Hirschfeld, Mar suppl 36
Effects of pregnancy on preexisting panic disorder. Villeponteaux, June 201–203
Examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder. Gelernter, Jan 23–27
Fluoxetine treatment of slow eating [letter]. Galynker, Aug 295–296
Introduction. Current perspectives on panic disorder and major depression. Hirschfeld, Mar suppl 3–4
Medication discontinuation in panic disorder. Ballenger, Mar suppl 26–31
Night terrors in adults: phenomenology and relationship to psychopathology. Llorente, Nov 392–394
Oral contraceptives and panic disorder. Deci, May 163–165
Simultaneous major depression and panic disorder: treatment with electroconvulsive therapy. Figiel, Jan 12–15
Suicide risk factors in depressive disorders and in panic disorder. Fawcett, Mar suppl 9–13
Treatments for panic disorder. Klerman, Mar suppl 14–19
Use of low-dose intranasal midazolam to treat panic disorder: a pilot study. Schweizer, Jan 19–22
Parkinson's Disease
Clozapine treatment of psychosis in Parkinson's

disease: a report of five consecutive cases. Wolk, Oct 373–376
Does fluoxetine exacerbate Parkinson's disease? Caley, Aug 278–282
Parnate
Parnate formulation change [letter]. Malen; Murabito reply, Sept 328–329
Paroxetine
Conclusions. A clinical profile of paroxetine: a novel selective serotonin reuptake inhibitor (SSRI). Boyer, Feb suppl 67–68
Double-blind comparison of paroxetine, imipramine, and placebo in major depression. Shrivastava, Feb suppl 48–51
Double-blind, placebo-controlled study of paroxetine in depressed outpatients. Kiev, Feb suppl 27–29
Efficacy and safety of paroxetine compared with placebo in outpatients with major depression. Rickels, Feb suppl 30–32
Optimal dose regimen for paroxetine. Dunner, Feb suppl 21–26
Overview of paroxetine. Boyer, Feb suppl 3–6
Paroxetine in major depression: a double-blind trial with imipramine and placebo. Cohn, Feb suppl 52–56
Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Feighner, Feb suppl 44–47
Paroxetine versus placebo: a double-blind comparison in depressed patients. Claghorn, Dec 434–438
Pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. Tulloch, Feb suppl 7–12
Placebo-controlled trial of paroxetine in the treatment of major depression. Smith, Feb suppl 36–39
Safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Claghorn, Feb suppl 33–35
Safety profile of paroxetine. Boyer, Feb suppl 61–66
Six-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Fabre, Feb suppl 40–43
Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Dunner, Feb suppl 57–60
Personality Disorders
Personality and clinical characteristics in patients with trichotillomania. Christenson, Nov 407–413
Personality disorder diagnoses in patients with bulimia nervosa: clinical correlates and changes with treatment. Ames-Frankel, Mar 90–96
Prevalence of personality disorders in 210 women with eating disorders. Herzog, May 147–152
Pharmacists
Pharmacist's role in the recognition and management of insomnia. Wincor, Dec suppl 80–83
Pharmacotherapy see Drug Therapy
Phenothiazines
Phenothiazine-induced lupus anticoagulant [letter]. Kaslow, Mar 103–104
Phobias
Examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder. Gelernter, Jan 23–27
Paraphilias, nonparaphilic sexual addictions, and social phobia [letter]. Golwyn, Sept 330
Treatment outcome of obsessive compulsive disorder with comorbid social phobia. Carrasco, Nov 387–391
Phototherapy
Gradual versus rapid dawn simulation treatment of winter depression. Avery, Oct 359–363
Pick's Disease
Case of early-onset Pick's disease [letter]. Stewart, Oct 380
Pimozide
Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. Stein, Apr 123–126
New possible indications of pimozide [letter]. Iruela; Opler reply, May 172–173
Postpartum Psychosis
Response to sleep deprivation in three women with postpartum psychosis. Strouse, June 204–206
Posttraumatic Stress Disorder
Psychophysiologic response during script-driven imagery as an outcome measure in posttraumatic stress disorder. Shalev, Sept 324–326
Potassium
Potassium supplementation in lithium patients: a timely intervention or premature speculation? Jefferson, Oct 370–372
Prediction
Symptomatic predictors of ECT response in medication-nonresponsive manic patients. Schnur, Feb 63–66
Pregnancy
Effects of pregnancy on preexisting panic disorder. Villeponteaux, June 201–203
Premenstrual Syndrome
Single-dose fluoxetine in management of premenstrual syndrome [letter]. Daamen, June 210–211
Primary Care
Proper use of sleeping pills in the primary care setting. Dement, Dec suppl 50–56
Psychiatrists
In memoriam: William W.K. Zung, 1929–1992 [editorial]. Brodie, June 182–183
Psychiatrists and physical illness: clarification [letter]. DuRand, June 213
Psychosis see also specific diagnoses
AIDS-related psychosis with catatonia responding to low-dose lorazepam [letter]. Scamvougeras, Nov 414–415
Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. Wolk, Oct 373–376
Diagnostic confusion in treatment-refractory psychotic patients. Smith, June 197–200
DSM-III-R brief reactive psychosis among Air Force recruits. Beighley, Aug 283–288
HIV-related psychosis [letter]. El-Mallakh, Aug 293–294
New possible indications of pimozide [letter]. Iruela; Opler reply, May 172–173
Paranoid psychosis, epidermoid tumor, and epilepsy: "symptomatic" psychosis or coincidence [letter]? Weller, July 257–258
Serotonin activity in psychotic (delusional) major depression. Schatzberg, Oct suppl 52–55
Psychostimulants
Should psychostimulants be used to treat delirious patients with depressed mood [letter]? Levenson; Ahmed reply, Feb 69
Psychotherapy
Nonpharmacologic treatments of insomnia. Bootzin, June suppl 37–41
Restraint, Physical
Restraint, seclusion and clozapine. Mallya, Nov 395–397
Schizophrenia
"Gedankenlautwerden" and datura intoxication [letter]. Goates, Apr 137
Introduction and overview to clinical applications of neuroSPECT in psychiatry. Schuckit, Nov suppl 3–6
Regional cerebral blood flow imaging with SPECT in psychiatric disease: focus on schizophrenia, anxiety disorders, and substance abuse. Woods, Nov suppl 20–25
Response of negative symptoms of schizophrenia to neuroleptic treatment. Serban, July 229–234
Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? Levin, July 248–251
Seasonal Affective Disorder
Efficacy of bupropion in winter depression: results of an open trial. Dilsaver, July 252–255
Gradual versus rapid dawn simulation treatment of winter depression. Avery, Oct 359–363
Seclusion
Restraint, seclusion and clozapine. Mallya, Nov 395–397
Sedative Hypnotics
Nonsedating treatments for Alzheimer's patients with behavioral problems [letter]. Hawkins; Goad reply, Mar 101–102
Seizures
Clozapine-induced myoclonic jerks and drop attacks [letter]. Berman, Sept 329–330
Methylphenidate and seizure frequency in brain injured patients with seizure disorders. Wroblewski, Mar 86–89
Tricyclic antidepressant-induced seizures and plasma drug concentration. Preskorn, May 160–162
Serotonin
Aggression, suicidality, and serotonin. Linnoila, Oct suppl 46–51
Basic advances in serotonin pharmacology. Fuller, Oct suppl 36–45
Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. Stein, Apr 123–126
Molecular biology of serotonin receptors. Harrington, Oct suppl 8–27
Neurochemical alterations of serotonergic neuronal systems in depression. Risch, Oct suppl 3–7
New directions in antidepressant therapy: a review of sertraline, a unique serotonin reuptake inhibitor. Sept Academic Highlights 333–340
Novel selective serotonin reuptake inhibitors, part I. Mar Academic Highlights 107–112
Novel selective serotonin reuptake inhibitors, part II. June Academic Highlights 216–221
Overview of paroxetine. Boyer, Feb suppl 3–6
Pharmacokinetics of the selective serotonin reuptake inhibitors. DeVane, Feb suppl 13–20
Pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. Tulloch, Feb suppl 7–12
Pharmacotherapy of obsessive compulsive disorder. Goodman, Apr suppl 29–37
Poor response to fluoxetine: underlying depres-

sion, serotonergic overstimulation, or a "therapeutic window"? Cain, Aug 272–277
Serotonergic antidepressants and their efficacy in obsessive compulsive disorder. Dominguez, Oct suppl 56–59
Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. Stein, Aug 267–271
Serotonin activity in psychotic (delusional) major depression. Schatzberg, Oct suppl 52–55
Serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. Barr, Apr suppl 17–28
Symptom relapse in bulimia nervosa and obsessive compulsive disorder after treatment with serotonin antagonists [letter]. Hollander, Jan 28
Treatment outcome of obsessive compulsive disorder with comorbid social phobia. Carrasco, Nov 387–391
Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. Hollander, June 207–209

Sertraline

New directions in antidepressant therapy: a review of sertraline, a unique serotonin reuptake inhibitor. Sept ACADEMIC HIGHLIGHTS 333–340

Sexual Disorders

Comparative study of nonparaphilic sexual addictions and paraphilias in men. Kafka, Oct 345–350
Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. Kafka, Oct 351–358
Paraphilias, nonparaphilic sexual addictions, and social phobia [letter]. Golwyn, Sept 330
Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. Stein, Aug 267–271

Sexual Dysfunction

Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. Jacobsen, Apr 119–122
Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment [letter]. Cohen, May 174
Treatment of fluoxetine-induced anorgasmia with amantadine [letter]. Balogh, June 212–213
Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. Hollander, June 207–209

Single Photon Emission Computed Tomography

Brain SPECT imaging and psychiatry. Van Heertum, Nov suppl 7–12
Comparison of SPECT applications in neurology and psychiatry. Devous Sr, Nov suppl 13–19
Current and future applications of SPECT in clinical psychiatry. Volkow, Nov 26–28
Introduction and overview to clinical applications of neuroSPECT in psychiatry. Schuckit, Nov suppl 3–6
Neuroreceptor imaging with SPECT. Innis, Nov suppl 29–34
Regional cerebral blood flow imaging with SPECT in psychiatric disease: focus on schizophrenia, anxiety disorders, and substance abuse. Woods, Nov suppl 20–25

Sleep

Clinical uses and advantages of low-doses of benzodiazepine hypnotics. Vogel, June suppl 19–22
Epidemiology and occurrence of insomnia. Rosekind, June suppl 4–6
Insomnia in the elderly. Monane, June suppl 23–28
Introduction. Current strategies in the treatment of insomnia. Mendelson, June suppl 3
Issues in the use of benzodiazepine therapy. Roth, June suppl 14–18
Night terrors in adults: phenomenology and relationship to psychopathology. Llorente, Nov 392–394
Nonpharmacologic treatments of insomnia. Bootzin, June suppl 37–41
Problem-solving approach to the treatment of insomnia: selected case histories. Trilling, June suppl 42–45
Proper use of sleeping pills in the primary care setting. Dement, Dec suppl 50–56
Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. Keck Jr, Apr 127–129
Response to sleep deprivation in three women with postpartum psychosis. Strouse, June 204–206
Sleep disorders in the medically ill patient. Moran, June suppl 29–36

Social Phobia see Phobias

Steroids

Anabolic steroid use among substance abusers in treatment. Clancy, Mar 97–100
Use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. Malone Jr, Apr 130–132

Substance Abuse

Anabolic steroid use among substance abusers in treatment. Clancy, Mar 97–100
Introduction and overview to clinical applications of neuroSPECT in psychiatry. Schuckit, Nov suppl 3–6
Mania self-induced with cough syrup [letter]. Mendez, May 173–174
Psychiatric comorbidity and suicidality among intravenous drug users. Dinwiddie, Oct 364–369
Regional cerebral blood flow imaging with SPECT in psychiatric disease: focus on schizophrenia, anxiety disorders, and substance abuse. Woods, Nov suppl 20–25

Suicide

Aggression, suicidality, and serotonin. Linnoila, Oct suppl 46–51
Akathisia, suicidality, and fluoxetine. Hamilton, Nov 401–406
Fluoxetine and suicidality [letter]. Pearlman; Rothschild reply, July 256–256
Lack of association between fluoxetine and suicidality in bulimia nervosa. Wheadon, July 235–241
Psychiatric comorbidity and suicidality among intravenous drug users. Dinwiddie, Oct 364–369
Suicidal and homicidal ideations emerging during a placebo period [letter]. Dominguez, May 171
Suicidality and fluoxetine revisited [letter]. Masand; Fava reply, Mar 102–103
Suicide risk factors in depressive disorders and in panic disorder. Fawcett, Mar suppl 9–13

Systemic Lupus Erythematosus

Phenothiazine-induced lupus anticoagulant [letter]. Kaslow, Mar 103–104

Thrombocytopenia

Carbamazepine-associated thrombocytopenia [letter]. Gordon; Tohen reply, Oct 378–379

Thyroid Disorders

T_3 augmentation of antidepressant treatment in T_4-replaced thyroid patients. Cooke, Jan 16–18

Thyroxine

T_3 augmentation of antidepressant treatment in T_4-replaced thyroid patients. Cooke, Jan 16–18

Tranylcypromine

Is tranylcypromine really metabolized to amphetamine [letter]? Jefferson; Zajecka reply, Dec 450–451
Parnate formulation change [letter]. Malen; Murabito reply, Sept 328–329

Trazodone

Possible trazodone potentiation of fluoxetine: a case series. Nierenberg, Mar 83–85

Triazolam

Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. Jonas, Dec suppl 19–31
Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature. Rothschild, Dec suppl 69–79
Review of triazolam data. Klett, Dec suppl 61–67

Trichotillomania

Clinical characteristics of trichotillomania and its response to fluoxetine. Winchel, Sept 304–308
Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. Stein, Apr 123–126
Personality and clinical characteristics in patients with trichotillomania. Christenson, Nov 407–413

Tryptophan

Acute tryptophan depletion: a method of studying antidepressant action. Miller, Oct suppl 28–35

Violence

Aggression, suicidality, and serotonin. Linnoila, Oct suppl 46–51
Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. Ratey, Feb 41–46

Vitamins

Bipolar disorder and Crohn's disease [letter]. Dommisse, Jan 29

Yohimbine

Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. Jacobsen, Apr 119–122
Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. Hollander, June 207–209

Journal of Clinical Psychiatry

Author Index to Volume 53: January 1992 Through December 1992

Abassian M see Lazarus LW

Ahmed I. Reply to Levenson JA: Should psychostimulants be used to treat delirious patients with depressed mood [letter]? Feb 69

Amado H. Review of Winokur G: *Mania and Depression: A Classification of Syndrome and Disease.* Dec 452

Ames D, Wirshing WC, Szuba MP. Organic mental disorders associated with bupropion in three patients. Feb 53–55

Ames-Frankel J, Devlin MJ, Walsh BT, Strasser TJ, Sadik C, Oldham JM, Roose SP. Personality disorder diagnoses in patients with bulimia nervosa: clinical correlates and changes with treatment. Mar 90–96

Amsterdam J see Rickels K

Ancill RJ see Smith GN

Anthony DT see Stein DJ

Arana GW see Deci PA

Avery DH, Bolte MAP, Cohen S, Millet MS. Gradual versus rapid dawn simulation treatment of winter depression. Oct 359–363

Baird JW see Baker RW

Baker LA see Keller MB

Baker RW, Chengappa KNR, Baird JW, Steingard S, Christ MAG, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine. Dec 439–442

Ballenger JC. Medication discontinuation in panic disorder. Mar suppl 26–31

Ballenger JC see Santos AB; Villeponteaux VA

Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine [letter]. June 212–213

Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. Dec suppl 34–39

Barklage NE, Jefferson JW, Margolis D. Do monoamine oxidase inhibitors alter carbamazepine blood levels [letter]? July 258

Barnas C, Zwierzina H, Hummer M, Sperner-Unterweger B, Stern A, Fleischhacker WW. Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report. July 245–247

Barr LC, Goodman WK, Price LH, McDougle CJ, Charney DS. Serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. Apr suppl 17–28

Barr LC see Miller HL

Battle AO. Review of Evangelista A: *Dictionary of Hypnotism.* Mar 106

Battle AO. Review of Exner JE Jr: *The Rorschach: A Comprehensive System, Vol. 2: Interpretation, 2nd Ed.* Sept 331–332

Bauer RM see Stewart JT

Baxter LR Jr see Strouse TB

Beasley CM Jr see Wheadon DE

Beighley PS Jr, Brown GR, Thompson JW Jr. DSM-III-R brief reactive psychosis among Air Force recruits. Aug 283–288

Beitman BD. Review of Smith GR Jr: *Somatization Disorder in the Medical Setting.* May 175

Bemporad JR see Ratey JJ

Berman I, Zalma A, DuRand CJ, Green AI. Clozapine-induced myoclonic jerks and drop attacks [letter]. Sept 329–330

Bernet W. Review of The Workgroup on Psychiatric Practice in the Juvenile Court: *Handbook of Psychiatric Practice in the Juvenile Court.* Sept 331

Billings CK. Review of Roy-Byrne PP, Cowley DS (eds): *Benzodiazepines in Clinical Practice: Risks and Benefits.* Jan 31–32

Billings CK. Review of Scrignar CB (eds): *From Panic to Peace of Mind: Overcoming Panic and Agoraphobia.* Aug 297–298

Black B, Uhde TW. Acute dystonia and fluoxetine [letter]. Sept 327

Blashko CA. Review of Myers WA (ed): *New Techniques in the Psychotherapy of Older Patients.* July 259

Blazer DG. Introduction. Issues in the treatment of major depression: selection, efficacy, and safety. Sept suppl 3–4

Blumhardt CL see Boyer WF; Shrivastava RK

Bolte MAP see Avery DH

Bootzin RR, Perlis ML. Nonpharmacologic treatments of insomnia. June suppl 37–41

Boutros NN see Warner MD

Boyer WF. Conclusions. A clinical profile of paroxetine: a novel selective serotonin reuptake inhibitor. Feb suppl 67–68

Boyer WF, Blumhardt CL. Safety profile of paroxetine. Feb suppl 61–66

Boyer WF, Feighner JP. Overview of paroxetine. Feb suppl 3–6

Boyer WF see Feighner JP

Brink TL. Review of Locurto C: *Sense and Nonsense About IQ: The Case for Uniqueness.* May 176

Brodie HKH. In memoriam: William W. K. Zung, 1929–1992 [editorial]. June 182–183

Brown GR see Beighley PS Jr

Brown WA see Daamen MJ

Burke M see Preskorn SH

Burrows GD. Long-term clinical management of depressive disorders. Mar suppl 32–35

Burstein A. Fluoxetine-lithium treatment for kleptomania [letter]. Jan 28–29

Bystritsky A see Fogelson DL

Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? Aug 272–277

Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? Aug 278–282

Carrasco JL, Hollander E, Schneier FR, Liebowitz MR. Treatment outcome of obsessive compulsive disorder with comorbid social phobia. Nov 387–391

Carrasco JL see Hollander E

Casper RC. Review of Yates A: *Compulsive Exercise and the Eating Disorders: Toward an Integrated Theory of Activity.* Apr 141

Catapano F, Galderisi S. Depression and cerebral stroke. 1990 Sept suppl 9–12. Notice to the readers, Aug 293

Chang SS see Gurrera RJ

Charney DS see Barr LC; Miller HL

Chengappa KNR see Baker RW; Levin H

Chernoff-Clementz E see Christenson GA

Christ MAG see Baker RW

Christensen JF see White JC

Christenson GA, Chernoff-Clementz E, Clementz BA. Personality and clinical characteristics in patients with trichotillomania. Nov 407–413

Ciaranello RD see Harrington MA

Claghorn JL. Safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Feb suppl 33–35

Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC. Paroxetine versus placebo: a double-blind comparison in depressed patients. Dec 434–438

Clancy GP, Yates WR. Anabolic steroid use among substance abusers in treatment. Mar 97–100

Clary C see Rickels K; Schweizer E

Clementz BA see Christenson GA

Cloninger CR see Dinwiddie SH

Cohen AJ. Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment [letter]. May 174

Cohen AJ, Leckman JF. Sensory phenomena associated with Gilles de la Tourette's syndrome. Sept 319–323

Cohen S see Avery DH

Cohn CK see Dunner DL

Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. Feb suppl 52–56

Cohn JB see Dunner DL

Cole JO see Kane JM; Nierenberg AA

Coleman BS see Jonas J

Cooke RG, Joffe RT, Levitt AJ. T_3 augmentation of antidepressant treatment in T_4-replaced thyroid patients. Jan 16–18

Coplan JD, Taylor L, Gorman JM. Dexamethasone for the treatment of depression [letter]. Aug 293

Creelman WL see Lenox RH

Cummings JL. Review of Becker RE, Giacobini E (eds): *Alzheimer's Disease: Current Research in Early Diagnosis.* Mar 105

Currier MB see Llorente MD

Daamen MJ, Brown WA. Single-dose fluoxetine in management of premenstrual syndrome [letter]. June 210–211

Daehler ML see Ratey JJ

Dalack GW see Roose SP

DasGupta K, Jefferson JW, Kobak KA, Greist JH. Effect of enalapril on serum

lithium levels in healthy men. Nov 398–400
DasGupta K, Young A. Reply to Weller M: NMS and lethal catatonia [letter]. Aug 295
DeCaria CM see Hollander E
De Leon OA. Intermetamorphosis syndrome [letter]. Jan 29–30
Dement WC. Proper use of sleeping pills in the primary care setting. Dec suppl 50–56
DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. Feb suppl 13–20
Deci PA, Lydiard RB, Santos AB, Arana GW. Oral contraceptives and panic disorder. May 163–165
Delgado PL see Miller HL
Del Medico VJ see Dilsaver SC
Deustch SI see Kaslow KA
Dever AI see Schweizer E
Devlin MJ see Ames-Frankel J
Devous MD Sr. Comparison of SPECT applications in neurology and psychiatry. Nov suppl 13–19
Dewan M see Masand P
Dewan MJ see Popli AP
Dilsaver SC, Qamar AB, Del Medico VJ. Efficacy of bupropion in winter depression: results of an open trial. July 252–255
Dimeff RJ see Malone DA Jr
Dinwiddie SH, Reich T, Cloninger CR. Psychiatric comorbidity and suicidality among intravenous drug users. Oct 364–369
Djenderedjian AH, Ritchie MA. Review of Amchin J: *Psychiatric Diagnosis: A Biopsychosocial Approach.* July 259–260
Dominguez RA. Serotonergic antidepressants and their efficacy in obsessive compulsive disorder. Oct suppl 56–59
Dominguez RA, Goldstein BJ. Suicidal and homicidal ideations emerging during a placebo period [letter]. May 171
Dommisse J. Bipolar disorder and Crohn's disease [letter]. Jan 29
Doraiswamy PM see Figiel GS
Douglas CJ see Wolk SI
Dunbar GC see Claghorn JL; Dunner DL
Dunner DL, Cohn JB, Walshe T III , Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hartford JT, Hearst ED, Settle EC Jr, Menolascino FJ, Muller DJ. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Feb suppl 57–60
Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. Feb suppl 21–26
DuRand CJ, Knutsen EJ. Psychiatrists and physical illness: clarification [letter]. June 213
DuRand CJ see Berman I
Ehmann TS see Smith GN
Eisen JL see Rasmussen SA
El-Mallakh RS. HIV-related psychosis [letter]. Aug 293–294
Engelhardt CL see Walsh JK
Escobar JI see Goates MG
Evans DL see Kane JM
Fabre LF. Six-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Feb suppl 40–43
Fadden JSP. Nifedipine and nonresponse to antidepressants [letter with reply]. Nov 416–417
Fallon BA see Stein DJ
Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. Double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Mar 77–82
Fast GA see Preskorn SH
Faustman WO see Miller LS
Fava M, Rosenbaum JF. Reply to Masand P: Suicidality and fluoxetine revisited [letter]. Mar 103
Fawcett J. Suicide risk factors in depressive disorders and in panic disorder. Mar suppl 9–13
Fawcett J see Lazarus LW
Fawcett JA see Zajecka JM
Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Feb suppl 44–47
Feighner JP see Boyer WF; Dunner DL
Feinberg SS see Opler LA
Fennig S, Mauas L. Ofloxacin-induced delirium [letter]. Apr 137–138
Fiester SJ see Kane JM
Fieve RR see Dunner DL
Figiel GS, Zorumski CF, Doraiswamy PM, Mattingly GW, Jarvis MR. Simultaneous major depression and panic disorder: treatment with electroconvulsive therapy. Jan 12–15
Fleischhacker WW see Barnas C; Schwitzer J
Fletcher JR see Ratey JJ
Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? Dec 443–446
Fox I see Rickels K
Frank E see Thase ME
Friedman JH see Caley CF
Friedman M see Galynker I
Friedman R see Krupp LB
Fuchs D, Weiss G, Wachter H. Pathogenesis of chronic fatigue syndrome [letter with reply]. Aug 296
Fuller RW. Basic advances in serotonin pharmacology. Oct suppl 36–45
Gaffney M see Serban G
Galderisi S see Catapano F
Galynker I, McQuistion H, Kahn RS, Friedman M. Fluoxetine treatment of slow eating [letter]. Aug 295–296
Ganguli R see Levin H
Garde IB see Miller LS
Garlow SJ see Harrington MA
Gelenberg AJ. Closing remarks. Use of benzodiazepine hypnotics: a scientific examination of a clinical controversy. Dec suppl 87
Gelenberg AJ. If not now, when [editorial]? Aug 266
Gelenberg AJ. Imperfect drugs in an imperfect world [editorial]. Feb 39–40
Gelenberg AJ. Introduction. Use of benzodiazepine hypnotics: a scientific examination of a clinical controversy. Dec suppl 3
Gelenberg AJ. To all a good year [editorial]. Dec 424–425
Gelernter CS, Stein MB, Tancer ME, Uhde TW. Examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder. Jan 23–27
George MS, Post RM, Ketter TA, Marangell LB, Pazzaglia PJ. Clarification of alpidem as an antidepressant [letter with reply]. Feb 68
George MS, Trimble MR. Fluvoxamime-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder [letter with reply]. Oct 379
German ML see Fankhauser MP
Giannini AJ. Reply to Vicente YMR: de Clerambault's syndrome [letter]. Apr 139
Gilaberte I see Iruela LM
Glass L see Nierenberg AA
Glaudin V see Smith WT
Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. Dec 426–433
Goad DL. Reply to Hawkins JW: Nonsedating treatments for Alzheimer's patients with behavioral problems [letter]. Mar 102
Goates MG, Escobar JI. "Gedankenlautwerden" and datura intoxication [letter]. Apr 137
Gold DD Jr. Review of Addonizio G, Susman VL: *Neuroleptic Malignant Syndrome: A Clinical Approach.* Jan 31
Gold DD Jr. Review of Howells JG (ed): *The Concept of Schizophrenia: Historical Perspectives.* May 175–176
Gold DD Jr. Review of Volkow ND, Wolf AP (eds): *Positron Emission Tomography in Schizophrenia Research.* Apr 140
Goldstein BJ see Dominguez RA
Golwyn DH, Sevlie CP. Paraphilias, nonparaphilic sexual addictions, and social phobia [letter]. Sept 330
Goodman WK. Introduction. Obsessive compulsive disorder: integrating theory and practice. Apr suppl 3
Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive compulsive disorder. Apr suppl 29–37
Goodman WK see Barr LC
Gordon MA. Carbamazepine-associated thrombocytopenia [letter with reply]. Oct 378
Gorman JM see Coplan JD
Greason FC see Hill MA
Green AI see Berman I
Greenblatt DJ. Pharmacology of benzodiazepine hypnotics. June suppl 7–13
Greist JH. Integrated approach to treatment of obsessive compulsive disorder. Apr suppl 38–41
Greist JH see DasGupta K
Groves L see Lazarus LW
Gupta MA. Dangerous driving and eating disorders [letter]. Nov 416
Gurrera RJ, Chang SS, Romero JA. Comparison of diagnostic criteria for neuroleptic malignant syndrome. Feb 56–62
Halikas JP see Dunner DL
Hamann GL, Wells BG. Reply to Reinke M: High incidence of haloperidol decanoate injection site reactions [letter]. Nov 415–416
Hamer T see Thase ME
Hamilton MS, Opler LA. Akathisia, suicidality, and fluoxetine. Nov 401–406
Hanson DR see Pfister GM
Harrington MA, Zhong P, Garlow SJ, Ciaranello RD. Molecular biology of serotonin receptors. Oct suppl 8–27
Harris GJ see Hoehn-Saric R
Hartford JT see Dunner DL
Hartman C see Lazarus LW
Hawkins JW. Nonsedating treatments for Alzheimer's patients with behavioral problems [letter with reply]. Mar 101–102
Hay J. Injection site reactions [letter]. July 256
Head LA see Jackson CW
Hearst ED see Dunner DL

Hendricks SE see Balogh S
Herzog DB, Keller MB, Lavori PW, Kenny GM, Sacks NR. Prevalence of personality disorders in 210 women with eating disorders. May 147–152
Hill FS. Review of Dulcan MK, Popper CW: *Concise Guide to Child and Adolescent Psychiatry*. Feb 70–71
Hill JL see Rubenstein CS
Hill MA, Greason FC. Loperamide dependence [letter]. Dec 450
Hirschfeld RMA. Closing remarks. Current perspectives on panic disorder and major depression. Mar suppl 36
Hirschfeld RMA. Introduction. Current perspectives on panic disorder and major depression. Mar suppl 3–4
Hoehn-Saric R, Harris GJ, Pearlson GD. Reply to George MS: Fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder [letter]. Oct 379–380
Hoffman MK see Stewart JT
Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. June 207–209
Hollander E, Mullen LS, Carrasco JL, DeCaria CM, Stein DJ. Symptom relapse in bulimia nervosa and obsessive compulsive disorder after treatment with serotonin antagonists [letter]. Jan 28
Hollander E see Carrasco JL; Stein DJ
Honer WG see Smith GN
Hummer M see Barnas C
Ibanez-Rojo V see Iruela LM
Innis RB. Neuroreceptor imaging with SPECT. Nov suppl 29–34
Iruela LM, Ibanez-Rojo V, Gilaberte I, Oliveros SC. New possible indications of pimozide [letter with reply]. May 172–173
Isaac G. Misdiagnosed bipolar disorder in adolescents in a special educational school and treatment program. Apr 133–136
Jackson CW, Head LA, Kellner CH. Catatonia associated with bupropion treatment [letter]. June 210
Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. Apr 119–122
Jarvis MR see Figiel GS
Jefferson JW. Is tranylcypromine really metabolized to amphetamine [letter with reply]? Dec 450–451
Jefferson JW. Potassium supplementation in lithium patients: a timely intervention or premature speculation? Oct 370–372
Jefferson JW see Barklage NE; DasGupta K
Joffe RT see Cooke RG
Johnson AM see Tulloch IF
Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. Dec suppl 19–31
Jones JS see Winchel RM
Kadish W see Ratey JJ
Kafka MP, Prentky R. Comparative study of nonparaphilic sexual addictions and paraphilias in men. Oct 345–350
Kafka MP, Prentky R. Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. Oct 351–358
Kahn RS see Galynker I
Kalinske RW see Jonas J
Kambhampati RK see Levin H
Kane JM, Evans DL, Fiester SJ, Mirin SM, Pincus HA, Schatzberg AF, Cole JO, Popper CW. Psychopharmacological screening criteria: APA Committee on Research on Psychiatric Treatments [special article]. June 184–196
Kane JM see Glazer WM
Kang J see Balogh S
Kartan U see Lazarus LW
Karumanchi SD see Fankhauser MP
Karumanchi VC see Fankhauser MP
Kaslow KA, Rosse RB, Zeller JA, Nagy MS, Deustch SI. Phenothiazine-induced lupus anticoagulant [letter]. Mar 103–104
Keck PE Jr, McElroy SL. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. Apr 127–129
Keitner GI. Review of Becker J, Kleinman A (eds): *Psychosocial Aspects of Depression*. Feb 71
Keller MB, Baker LA. Clinical course of panic disorder and depression. Mar suppl 5–8
Keller MB see Herzog DB
Kellner CH see Jackson CW
Kenny GM see Herzog DB
Ketter TA see George MS
Kiev A. Double-blind, placebo-controlled study of paroxetine in depressed outpatients. Feb suppl 27–29
Kiev A see Claghorn JL
King P. Review of Esman AH: *Adolescence and Culture*. Aug 298
Klein DF see Stein DJ
Klerman GL. Treatments for panic disorder. Mar suppl 14–19
Klett CJ. Review of triazolam data. Dec suppl 61–67
Knutsen EJ see DuRand CJ
Kobak KA see DasGupta K
Kores RC. Review of Butcher JN, Graham JR, Williams CL, Ben-Porath YS: *Development and Use of the MMPI-2 Content Scales*. Mar 105–106
Kornhuber J see Weller M
Kravitz K see Miller LS
Krupp LB, Friedman R, Mendelson WB. Reply to Wachter H: Pathogenesis of chronic fatigue syndrome [letter]. Aug 296
Kupfer DJ. Closing remarks. Use of benzodiazepine hypnotics: a scientific examination of a clinical controversy. Dec suppl 84–85
Kupfer DJ see Thase ME
Landbloom R see Pfister GM
Laraia MT see Villeponteaux VA
Larocca FEF. Review of Harper-Giuffre H, MacKenzie KR (eds): *Group Psychotherapy for Eating Disorders*. Nov 418
Lavori PW see Herzog DB
Lazarus LW, Winemiller DR, Lingam VR, Neyman I, Hartman C, Abassian M, Kartan U, Groves L, Fawcett J. Efficacy and side effects of methylphenidate for poststroke depression. Dec 447–449
Leary JM see Wroblewski BA
Leckman JF see Cohen AJ
Lee C see Schnur DB
Lefler LA see Stewart JT
Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. Feb 47–52
Leonard HL see Rapoport JL
Leong GB see Silva JA
Leuchter AF see Szuba MP
Levenson JA. Should psychostimulants be used to treat delirious patients with depressed mood [letter]? Feb 69
Levin H, Chengappa KNR, Kambhampati RK, Mahdavi N, Ganguli R. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? July 248–251
Levine SB. Review of Socarides CW, Volkan VD (eds): *The Homosexualities: Reality, Fantasy, and the Arts*. Oct 381
Levitt AJ see Cooke RG
L'Heureux F see Rubenstein CS
Licinio J see Miller HL
Liebowitz MR see Carrasco JL; Stein DJ
Lindem KJ see Ratey JJ
Lingam VR see Lazarus LW
Linnoila VMI, Virkkunen M. Aggression, suicidality, and serotonin. Oct suppl 46–51
Llorente MD, Currier MB, Norman SE, Mellman TA. Night terrors in adults: phenomenology and relationship to psychopathology. Nov 392–394
Locke CA see Rothschild AJ
Lydiard RB see Deci PA; Villeponteaux VA
MacEwan GW see Smith GN
Mahdavi N see Levin H
Malen DG. Parnate formulation change [letter with reply]. Sept 328–329
Mallinger AG see Thase ME
Mallya AR, Roos PD, Roebuck–Colgan K. Restraint, seclusion and clozapine. Nov 395–397
Malone DA Jr, Dimeff RJ. Use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. Apr 130–132
Mandos LA see Schweizer E
Manning K see Wroblewski B
Marangell LB see George MS
Margolis D see Barklage NE
Martinez IL see Vicente YMR
Maruyama N see Snyder S
Masand P, Dewan M. Suicidality and fluoxetine revisited [letter with reply]. Mar 102–103
Masand PS see Popli AP
Masica DN see Wheadon DE
Mattingly GW see Figiel GS
Mauas L see Fennig S
Mavissakalian M. Review of Turner SM, Calhoun KS, Adams HE (eds): *Handbook of Clinical Behavior Therapy*. Nov 419
Mazza DL. Review of Schwartz HJ, Silver A-L (eds): *Illness in the Analyst*. Oct 382
McCarley A see Hollander E
McDougle CJ see Barr LC; Goodman WK
McElroy SL see Keck PE Jr
McQuistion H see Galynker I
Mellman TA see Llorente MD
Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. Dec suppl 4–7
Mendelson WB. Introduction. Current strategies in the treatment of insomnia. June suppl 3
Mendelson WB. Review of Koulack D: *To Catch a Dream*. Aug 297
Mendelson WB see Krupp LB
Mendez MF. Mania self-induced with cough syrup [letter]. May 173–174
Menolascino FJ see Dunner DL
Mercier MA, Stewart JW, Quitkin FM. Pilot

sequential study of cognitive therapy and pharmacotherapy of atypical depression. May 166–170
Miller HL, Delgado PL, Salomon RM, Licinio J, Barr LC, Charney DS. Acute tryptophan depletion: a method of studying antidepressant action. Oct suppl 28–35
Miller LS, Garde IB, Moses JA Jr, Zipursky RB, Kravitz K, Faustman WO. Head injury and mood disturbance [letter]. May 171–172
Millet MS see Avery DH
Mirin SM see Kane JM
Molcho A see Winchel RM
Monane M. Insomnia in the elderly. June suppl 23–28
Moran MG, Stoudemire A. Sleep disorders in the medically ill patient. June suppl 29–36
Moses JA Jr see Miller LS
Mukherjee S see Schnur DB
Mullen LS see Hollander E
Muller DJ see Dunner DL
Muller U see Weller M
Murabito AS, Young ML. Reply to Malen DG: Parnate formulation change [letter]. Sept 328–329
Murphy DL see Rubenstein CS
Nagy MS see Kaslow KA
Nasrallah HA. Review of Cutting J: *The Right Cerebral Hemisphere and Psychiatric Disorders*. Apr 140
Nemeroff CB see Risch SC
Neudorfer C see Schwitzer J
Newhouse PA see Lenox RH
Neyman I see Lazarus LW
Nierenberg AA. Medical consequences of the selection of an antidepressant. Sept suppl 19–24
Nierenberg AA. Reply to Fadden JSP: Nifedipine and nonresponse to antidepressants [letter]. Nov 417
Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. Mar 83–85
Nino-Murcia. Diagnosis and treatment of insomnia and risks associated with lack of treatment. Dec suppl 43–47
Norman SE see Llorente MD
Novac A. Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD [letter]. Feb 67
O'Driscoll GA see Ratey JJ
Oldham J see Ames-Frankel J
Oliveros SC see Iruela LM
Opler LA, Feinberg SS. Reply to Iruela LM: New possible indications of pimozide [letter]. May 173
Opler LA see Hamilton MS
Orr SP see Shalev AY
Overweg N see Shrivastava RK
Pasnau R see Fogelson DL
Pazzaglia PJ see George MS
Peabody CA see Warner MD
Pearlman T. Fluoxetine and suicidality [letter with reply]. July 256–257
Pearlson GD see Hoehn-Saric R
Perlis ML see Bootzin RR
Petrides G see Sommer BR
Pfister GM, Hanson DR, Roerig JL, Landloom R, Popkin MK. Clozapine-induced agranulocytosis in a native American: HLA typing and further support for an immune-mediated mechanism. July 242–244
Phelan AM see Wroblewski BA
Pigott TA see Rubenstein CS
Pincus HA see Kane JM
Pitman RK see Shalev AY
Polakoff S see Ratey JJ
Pomeroy JC. Review of Feinstein SC (ed): *Adolescent Psychiatry, Volume 17*. Feb 71
Popkin MK see Pfister GM
Popli AP, Masand PS, Dewan MJ. Factitious disorders with psychological symptoms. Sept 315–318
Popper CW see Kane JM
Post RM see George MS
Potvin JH see Wheadon DE
Prentky R see Kafka MP
Prenzlauer S see Snyder S
Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. Sept suppl 5–18
Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. May 160–162
Price LH see Barr LC; Goodman WK
Qamar AB see Dilsaver SC
Quitkin FM see Mercier MA
Rampey AH Jr see Wheadon DE
Rapoport JL, Swedo SE, Leonard HL. Childhood obsessive compulsive disorder. Apr suppl 11–16
Rasmussen SA, Eisen JL. Epidemiology and differential diagnosis of obsessive compulsive disorder. Apr suppl 4–10
Ratey JJ, Sorgi P, O'Driscoll GA, Sands S, Daehler ML, Fletcher JR, Kadish W, Spruiell G, Polakoff S, Lindem KJ, Bemporad JR, Richardson L, Rosenfeld B. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. Feb 41–46
Reich T see Dinwiddie SH
Reinke M, Wiesert KN. High incidence of haloperidol decanoate injection site reactions [letter with reply]. Nov 415–416
Reynolds CF III. Treatment of depression in special populations. Sept suppl 45–53
Richardson L see Ratey JJ
Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. Efficacy and safety of paroxetine compared with placebo in outpatients with major depression. Feb suppl 30–32
Rickels K see Claghorn JL
Risch SC, Nemeroff CB. Neurochemical alterations of serotonergic neuronal systems in depression. Oct suppl 3–7
Ritchie MA see Djenderedjian AH
Rodgers C. Review of Weeks GR (ed): *Promoting Change Through Paradoxical Therapy, rev. ed.* July 260
Roebuck-Colgan K see Mallya AR
Roehrs TA see Roth T
Roerig JL see Pfister GM
Romero JA see Gurrera RJ
Roos PD see Mallya AR
Roose SP, Dalack GW. Treating the depressed patient with cardiovascular problems. Sept suppl 25–31
Roose SP see Ames-Frankel J
Rose DN see Snyder S
Rosebush PI see Scamvougeras A
Rosekind MR. Epidemiology and occurrence of insomnia. June suppl 4–6
Rosenbaum JF see Fava M
Rosenfeld B Rate JJ
Rosse RB see Kaslow KA
Roth SD see Schnur DB
Roth T, Roehrs TA. Issues in the use of benzodiazepine therapy. June suppl 14–18
Rothschild AJ. Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature. Dec suppl 69–79
Rothschild AJ, Locke CA. Reply to Pearlman T: Fluoxetine and suicidality [letter]. July 256–257
Rothschild AJ see Schatzberg AF
Rubenstein CS, Pigott TA, L'Heureux F, Hill JL, Murphy DL. Preliminary investigation of the lifetime prevalence of anorexia and bulimia nervosa in patients with obsessive compulsive disorder. Sept 309–314
Sackeim HA see Schnur DB
Sacks NR see Herzog DB
Sadik C see Ames-Frankel J
Salomon RM see Miller HL
Sands S See Ratey JJ
Santos AB, Ballenger JC. Tricyclic antidepressant triggers mania in patient with organic affective disorder [letter]. Oct 377–378
Santos AB see Deci PA
Scamvougeras A, Rosebush PI. AIDS-related psychosis with catatonia responding to low-dose lorazepam [letter]. Nov 414–415
Schatzberg AF. Recent developments in the acute somatic treatment of major depression. Mar suppl 20–25
Schatzberg AF, Rothschild AJ. Serotonin activity in psychotic (delusional) major depression. Oct suppl 52–55
Schatzberg AF see Kane JM
Schett P see Schwitzer J
Schneck JM. Fregoli syndrome: an unusual appearance in fiction [letter]. Mar 101
Schneier FR see Carrasco JL, Stein DJ
Schnur DB, Mukherjee S, Sackeim HA, Lee C, Roth SD. Symptomatic predictors of ECT response in medication-nonresponsive manic patients. Feb 63–66
Schooler NR see Baker RW
Schuckit MA. Introduction and overview to clinical applications of neuroSPECT in psychiatry. Nov suppl 3–6
Schweizer E, Clary C, Dever AI, Mandos LA. Use of low-dose intranasal midazolam to treat panic disorder: a pilot study. Jan 19–22
Schweizer E see Rickels K
Schwitzer J, Neudorfer C, Schett P, Fleischhacker WW. Usefulness of screening EEGs in psychiatric inpatients [letter with reply]. Sept 327–328
Segraves RT. Review of Arndt WB Jr: *Gender Disorders and the Paraphilias*. June 215
Seijo JCG see Vicente YMR
Serban G, Siegal S. Gaffney M. Response of negative symptoms of schizophrenia to neuroleptic treatment. July 229–234
Settle EC Jr see Dunner DL
Sevlie CP see Golwyn DH
Shalev AY, Orr SP, Pitman RK. Psychophysiologic response during script-driven imagery as an outcome measure in posttraumatic stress disorder. Sept 324–326
Sheridan AQ see Jonas J
Shrivastava RK, Shrivastava SHP, Overweg N, Blumhardt CL. Double-blind comparison of paroxetine, imipramine, and placebo in

major depression. Feb suppl 48–51
Shrivastava SHP see Shrivastava RK
Siegel S see Serban G
Silva JA, Leong GB. Case of Capgras-Fregoli syndrome [letter]. Feb 67–68
Singer CM see White JC
Smith GN, MacEwan GW, Ancill RJ, Honer WG, Ehmann TS. Diagnostic confusion in treatment-refractory psychotic patient. June 197–200
Smith WT, Glaudin V. Placebo-controlled trial of paroxetine in the treatment of major depression. Feb suppl 36–39
Smith WT see Claghorn JL
Snyder S, Prenzlauer S, Maruyama N, Rose DN. Catatonia in a patient with AIDS-related dementia [letter]. Nov 414
Soltys SM. Review of Hendren RL, Berlin IN (eds): *Psychiatric Inpatient Care of Children and Adolescents: A Multi-Cultural Approach.* Apr 140–141
Soltys SM. Review of Trad PV: *Interventions With Infants and Parents: The Theory and Practice of Previewing.* Nov 418–419
Sommer BR, Petrides G. Case of baclofen-induced psychotic depression [letter]. June 211–212
Sorgi P see Ratey JJ
Sperner-Unterweger B see Barnas C
Spruiell G see Ratey JJ
Stanley B see Winchel RM
Stanley M see Winchel RM
Steingard S see Baker RW
Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. Apr 123–126
Stein DJ, Hollander E, Anthony DT, Schneier FR, Fallon BA, Liebowitz MR, Klein DF. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. Aug 267–271
Stein DJ see Hollander E
Stein MB see Gelernter CS
Stern A see Barnas C
Stewart JT, Ware MR, Bauer RM, Hoffman MK, Lefler LA. Case of early-onset Pick's disease [letter]. Oct 380
Stewart JW see Mercier MA
St. John R. Review of Horowitz MJ (ed): *Person Schemas and Maladaptive Interpersonal Patterns.* Sept 331
Stone MH. Unreviewed books [letter]. June 214
Stone MH. Review of Socarides CW, Volkan VD (eds): *The Homosexualities and the Therapeutic Process.* Oct 381–382
Stoudemire A. Review of Weiner MF (ed): *The Dementias: Diagnosis and Management.* July 260
Stoudemire A see Moran MG
Stovall JG. Review of Rhodes LA: *Emptying Beds: The Work of an Emergency Psychiatric Unit.* June 215
Stuart GW see Villeponteaux VA
Strasser TJ see Ames-Frankel J
Strouse TB, Szuba MP, Baxter LR Jr. Response to sleep deprivation in three women with postpartum psychosis. June 204–206
Surawicz FG. Review of Falco KL: *Psychotherapy With Lesbian Clients: Theory Into Practice.* Sept 332
Surawicz FG. Review of Levine SB: *Sex is Not Simple.* Jan 32
Surawicz FG. Review of Schlaifer C, Freeman L: *Heart's Work: Civil War Heroine and Champion of the Mentally Ill, Dorothea Lynde Dix.* Nov 418
Surawicz FG. Review of Serafica FC, Schwebel AI, Russell RK, Isaac PD, Myers LB (eds): *Mental Health of Ethnic Minorities.* June 214
Surawicz FG. Review of Stotland NL (ed): *Psychiatric Aspects of Abortion.* May 175
Swedo SE see Rapoport JL
Szuba MP, Leuchter AF. Falling backward in two elderly patients taking bupropion. May 157–159
Szuba MP see Ames D; Strouse TB
Tanay E. Review of Committee on Psychiatry and Law of the Group for the Advancement of Psychiatry: *The Mental Health Professional and the Legal System.* Feb 70
Tancer ME see Gelernter CS
Tancredi L see Volkow ND
Taylor L see Coplan JD
Thaggard SL. Review of Stuber ML (ed): *Children and AIDS.* Nov 419
Thase ME. Long-term treatments of recurrent depressive disorders. Sept suppl 32–44
Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. Jan 5–11
Thompson JW Jr see Beighley PS Jr
Thompson VL see Wheadon DE
Tohen M. Reply to Gordon MA: Carbamazepine-associated thrombocytopenia [letter]. Oct 378–379
Tollefson GD. Reply to George MS: Clarification of alpidem as an antidepressant [letter]. Feb 68–69
Trilling JS. Problem-solving approach to the treatment of insomnia: selected case histories. June suppl 42–45
Trimble MR see George MS
Tulloch IF, Johnson AM. Pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. Feb suppl 7–12
Uhde TW see Black B; Gelernter CS
Uhlenhuth EH see Balter MB
Usdin G. Review of Lewis JM: *Swimming Upstream: Teaching and Learning Psychotherapy in a Biological Era.* Jan 32
Utley AC. Review of Greenspan SL, Greenspan NT: *The Clinical Interview of the Child.* June 214–215
Van Heertum RL. Brain SPECT imaging and psychiatry. Nov suppl 7–12
Vicente YMR, Seijo JCG, Martinez IL. de Clerambault's syndrome [letter with reply]. Apr 138–139
Villeponteaux VA, Lydiard RB, Laraia MT, Stuart GW, Ballenger JC. Effects of pregnancy on preexisting panic disorder. June 201–203
Virkkunen M see Linnoila VMI
Vogel G. Clinical uses and advantages of low doses of benzodiazepine hypnotics. June suppl 19–22
Volkow ND, Tancredi L. Current and future applications of SPECT in clinical psychiatry. Nov 26–28
Wachter H see Fuchs D
Walsh BT see Ames-Frankel J
Walsh JK, Engelhardt CL. Trends in the Pharmacologic Treatment of Insomnia. Dec suppl 10–17
Walshe T III see Dunner DL
Ware MR see Stewart JT
Warner MD, Peabody CA, Boutros NN. Reply to Schwitzer J: Usefulness of screening EEGs in psychiatric inpatients [letter]. Sept 328
Weise C see Rickels K
Weiss G see Fuchs D
Weller M. NMS and lethal catatonia [letter with reply]. Aug 294
Weller M, Muller U, Kornhuber J. Paranoid psychosis, epidermoid tumor, and epilepsy: "symptomatic" psychosis or coincidence [letter]? July 257–258
Wells BG see Hamann GL
Wheadon DE, Rampey AH Jr, Thompson VL, Potvin JH, Masica DN, Beasley CM Jr. Lack of association between fluoxetine and suicidality in bulimia nervosa. July 235–241
Whitaker TM see Lenox RH
White JC, Christensen JF, Singer CM. Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial. May 153–156
White K see Yonkers KA
Whyte J see Wroblewski BA
Wiesert KN see Reinke M
Wilcox CS see Cohn JB
Winchel RM, Jones JS, Stanley B, Molcho A, Stanley M. Clinical characteristics of trichotillomania and its response to fluoxetine. Sept 304–308
Wincor MZ. Closing remarks. Use of benzodiazepine hypnotics: a scientific examination of a clinical controversy. Dec suppl 85–87
Wincor MZ. Pharmacist's role in the recognition and management of insomnia. Dec suppl 80–83
Winemiller DR see Lazarus LW
Wirshing WC see Ames D
Wolk S, Douglas C. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. Oct 373–376
Woods SW. Regional cerebral blood flow imaging with SPECT in psychiatric disease: focus on schizophrenia, anxiety disorders, and substance abuse. Nov suppl 20–25
Wroblewski BA, Leary JM, Phelan AM, Whyte J, Manning K. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. Mar 86–89
Yates A see Fankhauser MP
Yates WR see Clancy GP
Yonkers KA, White K. Premenstrual exacerbation of depression: one process or two? Aug 289–292
Young A see DasGupta K
Young ML see Murabito AS
Zajecka JM, Fawcett JA. Reply to Jefferson JW: Is tranylcypromine really metabolized to amphetamine [letter]? Dec 450–451
Zalma A see Berman I
Zeller JA see Kaslow KA
Zhong P see Harrington MA
Zipursky RB see Miller LS
Zorumski CF see Figiel GS
Zwierzina H see Barnas C